Saltar al contenido
Merck

PHR1143

Supelco

Lisinopril

Pharmaceutical Secondary Standard; Certified Reference Material

Sinónimos:

(S)-1-[N2-(1-carboxy-3-phenylpropyl)-lysyl-proline dihydrate, MK-521

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C21H31O5N3 · 2H2O
Número de CAS:
Peso molecular:
441.52
Número MDL:
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
NACRES:
NA.24
En este momento no podemos mostrarle ni los precios ni la disponibilidad

grado

certified reference material
pharmaceutical secondary standard

Nivel de calidad

Agency

traceable to BP 695
traceable to Ph. Eur. L0702000
traceable to USP 1368609

familia API

lisinopril

CofA

current certificate can be downloaded

técnicas

HPLC: suitable
gas chromatography (GC): suitable

aplicaciones

pharmaceutical (small molecule)

Formato

neat

temp. de almacenamiento

2-30°C

cadena SMILES

[H]O[H].[H]O[H].NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N2CCC[C@H]2C(O)=O

InChI

1S/C21H31N3O5.2H2O/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15;;/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29);2*1H2/t16-,17-,18-;;/m0../s1

Clave InChI

CZRQXSDBMCMPNJ-ZUIPZQNBSA-N

Información sobre el gen

human ... ACE(1636)

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

Lisinopril is a lysine derivative of enalaprilat[1] and belongs to the group of angiotensin converting enzyme (ACE) inhibitors.[2] It is widely used as an orally active medication in the treatment of high blood pressure and may be used to treat congestive heart failure.[2][1]
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.

Aplicación

Lisinopril may be used as a pharmaceutical reference standard for the quantification of the analyte in pharmaceutical formulations using kinetic spectrophotometric technique.[2]
These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.

Acciones bioquímicas o fisiológicas

Angiotensin converting enzyme (ACE) inhibitor.

Nota de análisis

These secondary standards offer multi-traceability to the USP, EP (PhEur) and BP primary standards, where they are available.

Otras notas

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.
Values of analytes vary lot to lot.

Nota al pie de página

To see an example of a Certificate of Analysis for this material enter LRAB3302 in the slot below. This is an example certificate only and may not be the lot that you receive.

Pictogramas

Health hazard

Palabra de señalización

Danger

Frases de peligro

Clasificaciones de peligro

Repr. 1A - STOT RE 2

Órganos de actuación

Kidney

Código de clase de almacenamiento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Jason V Baker et al.
PloS one, 7(10), e46894-e46894 (2012-10-20)
Treatments that reduce inflammation and cardiovascular disease (CVD) risk among individuals with HIV infection receiving effective antiretroviral therapy (ART) are needed. We conducted a 2 × 2 factorial feasibility study of lisinopril (L) (10 mg daily) vs L-placebo in combination
Determination of lisinopril in pharmaceuticals by a kinetic spectrophotometric method
Cakar M and Popovic G
J. Serb. Chem. Soc., 77(10), 1437-1442 (2012)
Lisinopril
Lancaster GS and Todd AP
Drugs, 35(6), 646-669 (1988)
Saleh Yazdani et al.
PloS one, 7(11), e50209-e50209 (2012-11-29)
Proteinuria is an important cause of progressive tubulo-interstitial damage. Whether proteinuria could trigger a renal lymphangiogenic response has not been established. Moreover, the temporal relationship between development of fibrosis, inflammation and lymphangiogenesis in chronic progressive kidney disease is not clear
Xinjin Guo et al.
Toxicology and applied pharmacology, 271(2), 285-295 (2013-05-28)
We investigated the effects of JBP485 (an anti-inflammatory dipeptide and a substrate of OAT) on regulation of the expression and function of renal Oat1 and Oat3, which can accelerate the excretion of accumulated uremic toxins (e.g. indoxyl sulfate) in the

Questions

Reviews

No rating value

Active Filters

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico